Please assess the completion status of the following clinical trial:

Trial Title: Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed NSCLC~* Stage IIIb-Stage IV NSCLC~* ECOG performance status of 0-2~* Adequate liver and renal function~* Adequate bone marrow reserve~Exclusion Criteria:~* Treatment with neoadjuvant or adjuvant chemotherapy within 1 year~* Histologically confirmed mixed tumors containing small cell elements~* Treatment with radiotherapy (except limited in nature) within 3 weeks of randomization~* History of bone marrow transplantation or stem cell support~* Known history of CNS metastasis unless the patient has had treatment with surgery or radiotherapy, is neurologically stable and does not require oral or IV steroids or anticonvulsants~* History of HIV~* Grade 3 or 4 peripheral neuropathy~* Weightloss greater than 5% within 6 months~* Uncontrolled pleural effusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ezatiostat hydrochloride (Telintra®) (Type: EXPERIMENTAL): Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
- No Intervention (Type: NO_INTERVENTION): Chemotherapy with docetaxel and carboplatin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).